A Prospective Study of Hyperthermia Combined With Autologous Adoptive Cellular Immunotherapy in the Treatment of Abdominal and Pelvic Malignancies or Metastases
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Safety (adverse events)
研究概览
简要总结
It is a non-randomized pilot study.The allocation will be determined by patients or their immediate family members who were cooperative with physician's interpretations on the disease progression and updated information of cutting of edge treatment, the financial affordability, availability of treatment plans, possible tolerance or risks etc.The purpose of this study is to investigate the clinical efficacy and toxicity of autologous cellular immunotherapy combined with hyperthermia in abdominal and pelvic malignancies or metastases patients. Furthermore, to characterize response to different regimens,the investigators intent to explore the predictive and prognostic biomarker, as well as the changes in immune repertoire.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Abdominal and pelvic malignancies or metastases
- •Estimated life expectancy > 3 months
- •Age ≥ 18 years old
- •At least one measurable lesion according to the Solid Tumor Evaluation Criteria (RECIST Version 1.1)
- •Adequate hematologic function, with WBC ≥ 3000/microliter, hemoglobin ≥ 9 g/dL (it is acceptable to have had prior transfusion), platelets ≥ 75,000/microliter; PT-INR <1.5 (unless patient is receiving warfarin in which case PT-INR must be <3), PTT <1.5X ULN
- •Adequate renal and hepatic function, with serum creatinine < 1.5 mg/dL, bilirubin < 1.5 mg/dL (except for Gilbert's syndrome which will allow bilirubin ≤ 2.0 mg/dL), ALT and AST ≤ 2.5 x upper limit of normal.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2.
排除标准
- •Patients with a history of autoimmune disease, such as but not restricted to, inflammatory bowel disease, systemic lupus erythematosus, ankylosing spondylitis, scleroderma, or multiple sclerosis. Autoimmune related thyroid disease and vitiligo are permitted.
- •Patients with serious intercurrent chronic or acute illness, such as cardiac disease (NYHA class III or IV), hepatic disease, or other illness considered by the Principal Investigator as unwarranted high risk for investigational drug treatment.
- •Patients with a medical or psychological impediment to probable compliance with the protocol should be excluded.
- •Concurrent (or within the last 5 years) second malignancy other than non melanoma skin cancer, cervical carcinoma in situ, controlled superficial bladder cancer, or other carcinoma in situ that has been treated.
- •Presence of an active acute or chronic infection including: a urinary tract infection, HIV (as determined by ELISA and confirmed by Western Blot). Patients with HIV are excluded based on immuno-suppression, which may render them unable to respond to the vaccine; patients with chronic hepatitis are excluded because of concern that hepatitis could be exacerbated by the injections.
- •Patients on chronic steroid therapy (or other immuno-suppressives, such as azathioprine or cyclosporin A) are excluded on the basis of potential immune suppression. Patients must have had 6 weeks of discontinuation of any steroid therapy (except that used as pre-medication for chemotherapy or contrast-enhanced studies or for acute treatment (<5 days) of intercurrent medical condition such as a gout flare) prior to enrollment.
- •Pregnant and nursing women should be excluded from the protocol since this research may have unknown and harmful effects on an unborn child or on young children. If the patient is sexually active, the patient must agree to use a medically acceptable form of birth control while receiving treatment and for a period of 4 months following the last vaccination therapy. It is not known whether the treatment used in this study could affect the sperm and could potentially harm a child that may be fathered while on this study.
- •Patients with acute or chronic skin disorders that will interfere with injection into the skin of the extremities or subsequent assessment of potential skin reactions will be excluded.
- •There are metal stents or metal fixtures in the body
研究组 & 干预措施
HT+ACT
干预措施: Thermotron RF-8 (Device)
HT+ACT
干预措施: Adoptive cellular Immunotherapy (Biological)
HT+ACT+PD-1
干预措施: Thermotron RF-8 (Device)
HT+ACT+PD-1
干预措施: Adoptive cellular Immunotherapy (Biological)
HT+ACT+PD-1
干预措施: Anti-PD-1 antibody (Drug)
HT+ACT+CT
干预措施: Thermotron RF-8 (Device)
HT+ACT+CT
干预措施: Adoptive cellular Immunotherapy (Biological)
HT+ACT+CT
干预措施: Chemotherapy (Drug)
HT+CT
干预措施: Thermotron RF-8 (Device)
HT+CT
干预措施: Chemotherapy (Drug)
结局指标
主要结局
Safety (adverse events)
时间窗: 12 months
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
Objective response rate (ORR)
时间窗: 6 months
Proportion of patients with reduction in tumor burden of a predefined amount
次要结局
- Progression-free survival of the participants(PFS)(12 months)
- Assessment of Patient- Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)(12 months)
研究者
Jun Ren MD, PhD
Director,Capital Medical University (CMU)Cancer Center
Capital Medical University